Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Clinical trial NCT04201756 · COMPLETED

Trial details

NCT number: NCT04201756
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Adenocarcinoma Stage III EGFR Gene Mutation

Start date: 2020-07-26
Primary completion: 2022-02-28
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.